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Abstract
Background: Breast Cancer is the most commonly diagnosed cancer among Sri Lankan women.
Germline mutations in the susceptibility genes BRCA1 and BRCA2 in hereditary breast/ovarian
cancer, though low in prevalence, are highly penetrant and show geographical variations. There
have been only a few reports from Asia on mutations in BRCA1/2 genes and none from Sri Lanka.
Methods: A total of 130 patients with (N = 66) and without (N = 64) a family history of breast
cancer, 70 unaffected individuals with a family history of breast cancer and 40 control subjects were
analysed for BRCA1 mutations. All but exon 11 were screened by single strand conformation
analysis (SSCP) and heteroduplex analysis. PCR products which showed abnormal patterns in SSCP
were sequenced. Exon 11 was directly sequenced.
Results: Nineteen sequence variants were found in BRCA1 gene. Two novel deleterious frame-shift
mutations; c.3086delT/exon11 (in one patient) and c.5404delG/exon21 (in one patient and two of
her family members) were identified. A possibly pathogenic novel missense mutation (c.856T>G/
exon 11) and three novel intronic variants (IVS7+36C>T, IVS7+41C>T, IVS7+49del15) were
characterised. Ten previously reported common polymorphisms and three previously reported
intronic variants were also observed.
Conclusion: After screening of 66 patients with family history and 64 sporadic breast cancer
patients, 2 deleterious mutations (c.3086delT and c.5404delG) in two families were identified and
two more possibly pathogenic mutations (c.856T>G and IVS17-2A>T) in two families were
identified.
Data base: BRCA1 - Gene Bank: Accession # U14680 Version # 14680.1
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Background
Breast Cancer is the commonest malignancy in women
worldwide, accounting for 23% of all cancers and is sur-
passed only by lung cancer when cancers of both genders
are considered [1]. In Sri Lanka, breast cancer is the most
commonly diagnosed cancer among women, currently
accounting for 25% of cases. However, Sri Lanka has a
lower age standardized incidence rate of breast cancer
(18.25) compared to other Asian countries (range 18.7 to
33.3) and to North America (99.4) [1,2].
A number of risk factors are known to affect the likelihood
of developing breast cancer. Among them most potent are
the inherited mutations in the breast cancer susceptibility
(BRCA) gene 1 and 2 [3]. BRCA1 and BRCA2 mutations
are highly penetrant with a lifetime risk of 46–87% and
26–84% respectively of developing breast cancer by the
age of 70 years for mutation carriers [4-8]. BRCA1  is
located in 17q21 and consists of 24 exons coding for 1863
amino acids [9]. BRCA2 (13q12.3) consists 27 exons cod-
ing for 3418 amino acids [10]. BRCA1 and BRCA2 tumor
suppressor genes play a major role in DNA repair by
homologous recombination, maintenance of chromo-
somal stability, activation of DNA damage checkpoints,
transcription-coupled DNA repair, cell cycle regulation
and ubiquitylation [11-13].
To date more than 1600 sequence variants of BRCA1 and
1800 sequence variants of BRCA2 have been described
[14]. Some of these mutations were found only in specific
ethnic groups and hence referred to as founder mutations.
Due to these founder effects as well as due to other envi-
ronmental and geographical factors, the prevalence of
BRCA1 and BRCA2 mutations is variable among different
populations [15]. Many studies from the developed world
report the prevalence of BRCA1 and BRCA2 mutations of
breast cancer to vary from 1.8 – 13.1% [16-19]. Prevalence
of BRCA1 mutations in Asian countries vary from 0.8 to
8.6% [20-24]. In Sri Lanka, BRCA germ line mutations
have not been previously characterised.
In the present study, 130 breast cancer patients, 70 at risk
individuals and 40 control subjects were analysed for
BRCA1  mutations. We report here 2 novel deleterious
mutations, one novel possibly pathogenic mutation, three
novel intronic variants, ten reported polymorphisms and
three reported intronic variants.
Methods
Subjects
A total of 130 breast cancer patients (N = 66 with a family
history of breast cancer and N = 64 sporadic breast can-
cer), 70 at risk individuals (those without disease but with
a family history of breast cancer) and 40 healthy control
subjects without a personal or a family history of any can-
cer (N = 20 females and N = 20 males) were studied. At
risk individuals included 1, 2 or more first degree and sec-
ond-degree relatives of one affected patient. This also
included 5 first and 14 second degree relatives of one
breast cancer patient diagnosed at less than 35 years of
age. For 30 at risk individuals, their first and/or second-
degree relative breast cancer patients were included in this
study. Whereas for the rest, breast cancer patients had
already deceased and no blood samples were available for
analysis.
Mean age at diagnosis with breast cancer, number of fam-
ily members affected with breast cancer or other cancers
and ethnicity are summarised in Table 1. Thirty eight
patients were below 40 years of age at diagnosis. Thirty
three at risk individuals studied were below 40 years of
age. Of the 66 patients with familial breast cancer, 44 had
only one affected family member with 18 having an
affected first degree relative and 26 having an affected sec-
ond degree relative. Nineteen patients with familial breast
cancer had 2 family members affected, and of these 5 had
two affected first degree relatives, 11 had two affected sec-
ond degree relatives and each of the remaining 3 patients
had one first degree and one second degree relative with
breast cancer. Three patients with familial breast cancer
had one affected first degree relative and two affected sec-
ond degree relatives each.
Majority of the patients, at risk individuals and controls
were ethnically Sinhalese. There were no descendents of
Europeans. The study had ethical approval from the Insti-
tution Review Board. All the study participants gave writ-
ten informed consent to be included in the study. Patients
were recruited from the National Cancer Institute, Maha-
ragama and from those referred to Department of Pathol-
ogy, Faculty of Medicine, University of Colombo.
Unaffected individuals with a family history of breast can-
cer were from the Breast Clinic, National Cancer Institute,
Maharagama. Socio-demographic and clinical data were
obtained from the study participants and cancer diag-
noses were confirmed by reviewing medical reports and
pathology reports.
Molecular studies
Genomic DNA was isolated from peripheral blood lym-
phocytes from 10 ml blood samples using the protocol
described by Miller et al [25]. Specific primers were
selected from BIC primer database for PCR amplification
of all the exons of BRCA1 gene. The coding and neigh-
bouring intronic regions were screened by a combination
of single strand conformation analysis (SSCP) and heter-
oduplex analysis. Polymerase chain reaction (PCR) ampli-
fication was carried out in 25 μl volumes containing 50 ng
of genomic DNA, 3.5 mmol/l MgCl2, 1× PCR buffer [10
mM Tris-HCl (pH 8.3), 50 mM KCl], 2.5 mmol/l dNTPsBMC Cancer 2008, 8:214 http://www.biomedcentral.com/1471-2407/8/214
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(Promega, Madison, WI, USA), 5 pmols of each primer
and 0.5 U of Taq Polymerase (Promega). PCR reaction
was carried out for 33 cycles and the thermal cycling con-
ditions were denaturation at 94°C for 45 s, annealing at
the respective optimal temperature for 45 s and extension
at 72°C for 2 min. Optimal annealing temperature for dif-
ferent exons varied from 54°C to 60°C.
SSCP analysis was carried out by denaturing equal vol-
umes of PCR product of the sample with denaturing load-
ing buffer (95% formamide, 0.05% xylene cyanol, 0.05%
bromophenol blue) heated at 95°C for 5 min. Denatured
DNA were separated by polyacrylamide (10%) gel electro-
phoresis under non-denaturing conditions and run at 100
V for 8–10 h in 0.5 × TBE at 10–15°C). DNA fragments
were visualized by silver staining [26]. Heteroduplex anal-
ysis was done by mixing equal volumes of denaturing
loading buffer and a mixture of sample and normal con-
trol PCR products, denaturing at 95°C for 5 min and then
allowing to re-anneal by incubating for 10 min at room
temperature. The resulting double-stranded heteroduplex
molecules were visualized by silver staining. Samples giv-
ing abnormal migration patterns on SSCP were recon-
firmed using a second PCR product.
DNA sequencing
Samples which showed an abnormal pattern on SSCP
analysis were selected. DNA was eluted from the abnor-
mal polyacrylamide gel bands and re-amplified using the
same primers. PCR products were purified using GFX™
PCR DNA and Gel Band Purification Kit (GE Healthcare
Bio-Sciences Corp, Piscataway, NJ, USA). Both strands
were directly sequenced using a commercially available
Cy™ Dye Termination Kit using the MegaBACE 1000 auto-
mated DNA sequencer (GE Healthcare). Mutations and
sequence variants detected were reconfirmed by analysing
a second sample and a second PCR product respectively.
Exon 11 was analysed by direct sequencing. This analysis
was limited to 51 patients with a family history of breast
cancer, 22 at risk individuals (19 first and second degree
relatives of a patient detected to have a novel deleterious
mutation in exon 21 and 3 first degree relatives of a
patient detected to have a novel missense mutation in
exon 11 during the current study) and 22 controls.
Results and discussion
Breast cancer incidence in Sri Lanka has increased during
the last two decades. Mean age of onset at 47 years for
familial and sporadic breast cancer patients in this study
shows the importance of studying existence of genetic sus-
ceptibility in Sri Lankan breast cancer patients. A confirm-
ative genetic test for BRCA1  or  BRCA2  mutations can
markedly reduce cancer risk by prophylactic mastectomy
and oophorectomy [13].
This is the first report on BRCA1 mutations and polymor-
phisms in Sri Lankan breast cancer patients and at risk
individuals. We have identified 19 sequence variants in
BRCA1  gene (Tables 2 and 3). Two novel deleterious
frame-shift mutations, c.3086delT in exon 11 [BIC:
Table 1: Characteristics of patients and at risk individuals
Familial breast cancer patients 
(N = 66)
Sporadic breast cancer patients 
(N = 64)
At risk Individuals 
(N = 70)
Age (years) at diagnosis (patients)/sample 
collection (at risk individuals)
Mean ± SD 46.97+9.05 47.37+10.06 40.51+12.01
≤ 40 18 20 33
> 40 48 44 37
Number of family members with breast 
cancer
N = 0 0 64 0
N = 1 44 (1st: 18, 2nd: 26) 0 28
N = 2 19 (1st: 5, 2nd: 11, 1st & 2nd both: 3) 0 18
N = 3 03 (1st and 2nd)0 2 4
Number of family members with other 
cancers*
N = 1 16 0 17
N = 2 07 0 24
N = 3 01 0 01
N = 4 01 0 0
Ethnicity
Muslim 02 03 01
Sinhalese 62 58 68
Tamil 02 03 01
* colorectal, lung, oral, ovarian, thyroid, uterine cancers 1st: 1st degree relative, 2nd: 2nd degree relative affected with breast cancerBMC Cancer 2008, 8:214 http://www.biomedcentral.com/1471-2407/8/214
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AC:17840] and c.5404delG in exon 21 [BIC: 17841], and
one novel missense possibly pathogenic mutation,
c.856T>G in exon 11 [BIC: AC17839] were detected
(Table 2). Frame-shift mutation c.3086delT in exon 11
was observed in one breast cancer patient and c.5404delG
in exon 21 in one breast cancer patient, one of her first
degree and one second degree relative. Possibly patho-
genic, novel missense mutation c.856T>G in exon 11 was
seen in one breast cancer patient. Three novel intronic var-
iants (IVS7+36C>T, IVS7+41C>T, IVS7+49del15) were
found in exon 7 (Table 3) [BIC: AC17836, BIC: AC17837,
BIC: AC17838 respectively]. Ten previously reported pol-
ymorphisms in exons 11 [BIC: AC17844, BIC: AC17845,
BIC: AC17846, BIC: AC17847, BIC: AC17848, BIC:
AC17849], 13 [BIC: AC17850] and 16 [BIC: AC17851,
BIC: AC17852, BIC: AC17853] and one reported intronic
variant each in exons 7 [BIC: AC17842], 8 [BIC:
AC17843] and 18 [BIC: AC17854] were identified (Table
3).
SSCP analysis showed abnormal migration patterns in
polyacrylamide gels for exons 7, 8, 13, 16, 18 and 21.
Abnormal migration patterns in SSCP analysis of exon 21
were seen only in three study participants (III.12, III.16,
III.19) of a single sib ship (Figure 1). The pedigree of this
family (F-01) is shown in Figure 2. Direct sequencing
showed the presence of a novel frame shift mutation:
c.5404delG (codon 1762) resulting in a stop codon at
1764 of BRCA1 protein in all three of them. This family
was Sinhalese in ethnicity and had five individuals of
three different generations affected by breast, uterine and
salivary gland cancer. Out of the three with the mutation,
one (III.16) developed breast cancer at 33 years of age and
the other two were her first and second-degree female rel-
atives. However these two family members do not have
clinical or radiological evidence of breast cancer to date.
The patient and her sister carrying the same mutation were
the daughters of a breast cancer patient diagnosed with
the disease at 38 years of age. The second-degree female
relative who carries the same mutation was the daughter
of our breast cancer patient's maternal aunt who was diag-
nosed with uterine cancer at the age of 42 years. These
breast and uterine cancer patients in the FII generations
had deceased and no archival specimens were available
for genetic studies. We screened 19 first and second degree
living relatives of our index case (III.16) including her
three sisters and two brothers for BRCA1 mutations.
Table 2: Clearly pathogenic and possibly pathogenic BRCA1 mutations identified
E/I NT Base Change Codon AA Change Designation Variation type BIC Entry
11-A 856 T>G 246 Leu>TrP c.856T>G M-UV No
11-C 3086 delT 989 Stop999 c.3086delT F No
I-18 5194-2 A>T Non- coding -- IVS17-2A>T IVS Yes
21 5404 delG 1762 Stop1764 c.5404delG F No
E/I: Exon/Intron, F: frame shift, M: missense alteration, UV: unclassified variant
Table 3: Common polymorphisms and intronic variants of BRCA 1 gene identified
E/I NT Base Change Codon AA Change Designation Variation type BIC Entry
I-7 560+36 C>T Non- coding -- IVS7+36T>C UV No
I-7 560+38 T>C Non- coding -- IVS7+38T>C UV Yes
I-7 560+41 C>T Non- coding -- IVS7+41C>T UV No
I-7 560+49 DelT Non- coding -- IVS7+49del15 UV No
I-8 561-34 C>T Non- coding -- IVS7-34C>T IVS Yes
11-B 2196 G>A 693 Asp > Asn c.2196G>A M-P Yes
11-B 2201 C>T 694 Ser>Ser c.2201C>T Silent-P Yes
11-B 2430 T>C 771 Leu>Leu c.2430T>C Silent-P Yes
11-C 2731 C>T 871 Pro>Leu c.2731C>T M-P Yes
11-C 3232 A>G 1038 Glu>Gly c.3232A>G M-P Yes
11-D 3667 A>G 1183 Lys>Arg c.3667A>G M-P Yes
13 4427 T>C 1436 Ser>Ser c.4427T>C Silent-P Yes
16 4931 A>G 1604 Gln>Gln c.4931A>G Silent-P Yes
16 4956 A>G 1613 Ser>Gly c.4956A>G M-P Yes
16 5075 A>G 1652 Met>Ile c.5075G>A M-P Yes
E/I: Exon/Intron, M: missense alteration, P: polymorphism, UV: unclassified variantBMC Cancer 2008, 8:214 http://www.biomedcentral.com/1471-2407/8/214
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Mutation c.5404delG has not been previously reported in
the breast cancer information core [14]. It is present in the
area of two BRCT domains (a.a 1646–1859) of BRCA1
protein. BRCT domain is a unique feature of proteins
which are involved in DNA repair and check point control
[13]. One study has shown that even a BRCA1-BRCT mis-
sense mutation created a conformational change and
functional instability in BRCA1 protein [27]. According to
the BIC database, up to date only twelve exonic and nine
intronic variations have been identified in exon 21/
BRCA1 [14]. None of the Asian countries reported muta-
tions in exon 21 and a very few are reported from other
countries [28].
Deleterious frame shift mutation, c.3086delT in exon 11
was identified in one patient who developed breast cancer
at the age of 46 years. Her maternal grandmother who is
now deceased was diagnosed with breast cancer at 52
years of age. This frame shift mutation creates a stop
codon at 999 in BRCA1 protein and is located in the area
of DNA binding domain of BRCA1, which spans amino
acids 452 to1079. RAD51 binds to this area and it is a key
component of the DNA damage repair by homologous
recombination [13]. This mutation is therefore likely to
be of functional significance and further studies will be
needed to clarify its role.
One possibly pathogenic novel missense alteration
c.856T>G (exon 11) was found in a breast cancer patient
diagnosed at 45 years of age with a family history of breast
and uterine cancer. Her mother and a sister both of whom
are now deceased were diagnosed with breast cancer at the
age of 50 and 35 years respectively and a maternal aunt
was diagnosed with uterine cancer at 52 years of age. This
missense alteration converts amino acid leucine to tryp-
tophan at codon 246 of BRCA1. Both are nonpolar and
hydrophobic but the former is an aliphatic and the latter
an aromatic amino acid. Thus conformational changes in
the protein are possible. Three healthy first degree rela-
tives of this patient who were included in this study did
not carry c.856T>G mutation.
We identified 4 co-existing intronic variants IVS7+36C>T,
IVS7+38T>C, IVS7+41C>T and IVS7+49del15 in intron 7.
Except IVS7+38T>C, other three variants have not been
previously reported in BIC database. SSCP analysis
showed very clear banding patterns in normal, hetero-
zygous and homozygous individuals and sequencing of
eluted DNA confirmed the presence of 4 intronic variants
(Figure 3). 51 familial breast cancer patients, 55 sporadic
breast cancer patients, 61 at risk individuals and 28 con-
trol subjects had these 4 co-existing intronic variants with
an allele frequency of 0.48, 0.62, 0.60 and 0.54 respec-
tively. IVS7+38T>C has been previously reported from
India but only in one sporadic breast cancer patient [24].
We found one previously reported intronic variant each in
introns 8 and 18. IVS7-34C>T in exon 8 was found in two
patients with a family history of breast cancer. One of
them has two first degree relatives (mother and one sister)
and the other has two second degree relatives (maternal
grandmother and maternal aunt) affected with breast can-
cer. This variant has also been reported in Indian breast
cancer patients and there were 8 records of the same
sequence variant in BIC database. It does not appear to
show any clinical importance [14].
IVS17-2A>T in intron18 was found in a patient diagnosed
with breast cancer at the age of 35 years. Her mother who
is now deceased was diagnosed with uterine cancer and
mother's sister and her daughter were diagnosed with
breast cancer at the age of 55 and 32 years respectively.
According to BIC database this intronic variation located
at the splice-site of the intron is clinically important.
Nearly 5% of all BRCA1 and BRCA2 sequence alterations
are splice-site mutations (BIC database, 2007), but very
few studies have been carried out to identify the patho-
genic importance of these [29-31].
Common polymorphisms in BRCA1 gene appear to be
highly prevalent in Sri Lankan breast cancer patients and
in healthy controls. In this study, we found ten previously
SSCP analysis of PCR products of exon 21/BRCA1 Figure 1
SSCP analysis of PCR products of exon 21/BRCA1. 
Lane 3, 4 and 6 are samples with the c.5404delG mutation. 
Lane 2, 5 and 7 are wild type. Lane 1 is a non template con-
trol. a: additional band seen in the presence of mutation, b: 
banding pattern shown by wild type.BMC Cancer 2008, 8:214 http://www.biomedcentral.com/1471-2407/8/214
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reported polymorphisms c.2196G>A, c.2201C>T,
c.2430T>C, c.2731C>T, c.3232A>G, c.3667A>G in exon
11, c.4427T>C in exon 13 and c.4931A>G, c.4956A>G,
c.5075G>A in exon 16. The allele frequencies of some of
the polymorphisms observed by us were greater than what
has been reported by others (ie: allele frequencies of 0.35
or greater for c.2201C>T, c.2430T>C, c.3232A>G,
c.3667A>G, 0.52 or greater for c.4427T>C and 0.49 or
greater for c.4956A>G) [16,19,21,23,32-34]. However,
there was no discernible difference in these allele frequen-
cies between familial breast cancer, sporadic breast cancer,
at risk individuals and healthy controls in the present
study (data not shown).
Both c.4931A>G and c.4956A>G polymorphisms of exon
16 co-existed in three unrelated breast cancer patients
with a family history of breast cancer. Polymorphisms
c.5075G>A and c.4956A>G of exon 16 co-existed in 6
breast cancer patients, two at risk individuals and two
controls all of whom were un related. Co-existence of
c.4956A>G with c.4931A>G has not been reported previ-
ously. Although both c.4956A>G and c.5075G>A have
been reported from India and Italy, whether these co-
existed in the same individual has not been indicated
[19,24]. Other studies report a prevalence rate between
0.2% and 7% for c.5075G>A polymorphism [16,19,34]
We also identified a reported missense polymorphism
c.2196G>A in exon 11 of BRCA1  in a second degree
maternal relative (III.6) of our index case in family F-01.
She developed a benign breast tumour which was
removed by lumpectomy recently and also suffers from a
number of medical conditions namely, non-insulin
dependent diabetes mellitus, chronic obstructive airway
disorder, cervical spondylosis and hypertension. Her sis-
ter died of breast cancer at the age of 38 years. This partic-
ular polymorphism which converts Asp (negatively
charged) to Asn (polar uncharged) has been frequently
reported in different populations for example from Saudi
Arabia, Greece and Belgium [17,34,35].
Out of 20 members of F-01 family included in this study
one female member (IV.12) had no polymorphisms or
intronic variants whereas all other 19 members including
the breast cancer patient and two family members with
the exon 21 mutation had all six common polymor-
phisms and intron 7 variations reported in the present
study. The fact that one person with the exon 21 mutation
developed breast cancer and the other two with the exon
21 mutation are yet free from the disease suggest that the
six common polymorphisms and the intron 7 variations
are unlikely to predispose to or protect from the disease in
exon 21 mutation carriers.
Conclusion
We identified 19 sequence variants in BRCA1  gene by
screening 66 familial and 64 sporadic breast cancer
patients, 70 at risk individuals and 40 control subjects. Six
Pedigree of family F-01 Figure 2
Pedigree of family F-01. Age of onset of the disease for members affected with breast cancer, other cancers and benign 
breast disease indicated.BMC Cancer 2008, 8:214 http://www.biomedcentral.com/1471-2407/8/214
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of them were novel sequence variants. Two novel clearly
pathogenic (c.3086delT and c.5404delG) and 2 possibly
pathogenic [c.856T>G (novel) and IVS17-2A>T
(reported)] mutations were identified. Three novel un-
classified intronic variants; IVS7+36C>T, IVS7+41C>T,
IVS7+49del15, twelve common polymorphisms in exons
11, 13 and 16 and two common intronic variants in I- 7
and I-8 of BRCA1 gene were also identified. Prevalence of
BRCA1 mutations in our study was 6.25% (4/64) among
familial breast cancer patients. Co-existence of polymor-
phisms c.4956A>G and c.4931A>G in exon 16 of BRCA1
gene and co-existence of IVS7+36C>T, IVS7+38T>C,
IVS7+41C>T, IVS7+49del15 in I-7 of BRCA1 gene, have
not been previously reported. This study should be
extended to analyse a larger number of patients to identify
other pathogenic mutations in the BRCA 1 gene as well as
mutations in the BRCA 2 gene.
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